Despite numerous scientific, clinical and regulatory hurdles, the biomedical space remains a robust engine of innovation. Developments in medical devices, pharmacology, medical imaging and healthcare technology are poised to disrupt legacy systems and tackle the complex issues in healthcare. In many cases, successful commercialization of these solutions cannot proceed without the capital and distribution channels available to large acquirers. In turn, major industry players can leverage significant advantage by entering into strategic partnerships, acquisitions or licensing of the latest medical technology.
Glendale Capital Partners has the resources and access to medical science expertise to ensure that the next generation of biomedical solutions is made available to payers, providers and patients.